Latest article
Fierce Pharma Asia—AstraZeneca-Junshi PD-1 deal; Takeda’s $1.2B diabetes selloff, Ovid epilepsy collab pullout
In a strangely structured deal, AstraZeneca has nationwide licensed Junshi Biosciences' PD-1 inhibitor for only one indication in China. Takeda continued to sell...
Diabetes Mortality Charges Larger Amongst Blacks Than Whites – Shopper Well being Information
FRIDAY, April 2, 2021 (HealthDay News) - The diabetes death rate is higher among blacks than whites. According to a study published in...
New Free Health Initiative to Assist Individuals Publish Most cancers Restoration
Everyone knows someone in their middle or immediate environment who is affected by cancer.Battle Cancer changed the face of post-cancer support and launched...